SOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)

Ciruelos, E.Salvador Bofill, F. J.Perello Martorell, A.Alba Conejo, E.Gonzalez-Farre, X.Palacios-Ozores, P.Merino, M.Villagrasa, P.Vila Navarro, E.Pascual, T.Prat, A.Pernas Simon, S.2025-01-072025-01-072021-05-080923-7534https://hdl.handle.net/10668/27091enSOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)conference outputopen access10.1016/j.annonc.2021.03.0871569-8041http://www.annalsofoncology.org/article/S0923753421009650/pdf648924400075